Carve-outs for generics, European exports and companies onshoring drug production will likely shield most branded drugs from the 100% levies Trump announced Thursday. This development signals a strategic pivot in the administration’s approach to pharmaceutical pricing and trade, potentially easing the burden on key industry players.
As the pharmaceutical sector grapples with the implications of these tariffs, the exemptions could mitigate the anticipated disruptions in supply chains and pricing structures. By allowing generics and certain imports to bypass these steep tariffs, the administration may be attempting to balance domestic production incentives with the need for affordable medications in the market.
The implications for regulatory and sourcing professionals are significant; they must navigate this evolving landscape while ensuring compliance and maintaining supply chain integrity. The focus on onshoring also suggests a potential shift in CMC strategies, as companies may need to reassess their manufacturing locations and partnerships to align with new trade policies.
Use the database as your supply chain compass →
